by King, L. A., Lameris, R., de Gruijl, T. D., and van der Vliet, H. J. (2018). Front. Immunol. 9:1519. doi: 10.3389/fimmu.2018.01519 In the original article, we neglected to disclose that authors Lisa A. King and Roeland Lameris are currently funded by Lava Therapeutics and that Hans J. van der Vliet also acts as chief scientific officer of Lava Therapeutics. Hans J. van der Vliet's affiliation has been updated to reflect this. The corrected Conflict of Interest statement appears below.
King, L. A., Lameris, R., de Gruijl, T. D., & van der Vliet, H. J. (2018). Corrigendum : CD1d-invariant natural killer T cell-based cancer immunotherapy: α-galactosylceramide and beyond (Frontiers in Immunology (2018) 9 (1519) DOI: 10.3389/fimmu.2018.01519). Frontiers in Immunology, 9(NOV), . https://doi.org/10.3389/fimmu.2018.02606